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R. D. Riley,a* M. J. Price,b D. Jackson,c M. Wardle,d F. Gueyfﬁer,e
J. Wang,f J. A. Staesseng,h and I. R. WhitecWhen combining results across related studies, a multivariate meta-analysis allows the joint synthesis of
correlated effect estimates from multiple outcomes. Joint synthesis can improve efﬁciency over separate
univariate syntheses, may reduce selective outcome reporting biases, and enables joint inferences across
the outcomes. A common issue is that within-study correlations needed to ﬁt the multivariate model are
unknown from published reports. However, provision of individual participant data (IPD) allows them to
be calculated directly. Here, we illustrate how to use IPD to estimate within-study correlations, using a joint
linear regression for multiple continuous outcomes and bootstrapping methods for binary, survival and
mixed outcomes. In a meta-analysis of 10 hypertension trials, we then show how these methods enable
multivariate meta-analysis to address novel clinical questions about continuous, survival and binary
outcomes; treatment–covariate interactions; adjusted risk/prognostic factor effects; longitudinal data;
prognostic and multiparameter models; and multiple treatment comparisons. Both frequentist and
Bayesian approaches are applied, with example software code provided to derive within-study correlations
and to ﬁt the models. © 2014 The Authors. Research Synthesis Methods published by John Wiley & Sons, Ltd.
Keywords: multivariate meta-analysis; bivariate meta-analysis; multiple outcomes; correlation; individual
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In meta-analysis, multiple summary results are required when there are multiple effects of interest, such as
multiple outcomes (Berkey et al., 1995) or multiple time points (Dear, 1994). For example, in a meta-analysis of
hypertension trials, the treatment effect on both systolic blood pressure (SBP) and diastolic blood pressure
(DBP) will be of interest. In this situation, a multivariate meta-analysis model allows a joint synthesis of the multiple
outcomes (Raudenbush et al., 1988; Becker, 2000; Van Houwelingen et al., 2002; Jackson et al., 2011). This produces
a summary (pooled) effect for each outcome and accounts for any correlation in the outcome effects, which may
exist both within studies and between studies. Between-study correlation indicates how the true effects on the
outcomes are related across studies. It is caused by differences across studies in patient and study characteristics
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8diagnostic test studies, which modiﬁes both sensitivity and speciﬁcity (Reitsma et al., 2005). Within-study
correlations indicate the association between the estimates of effect on the outcomes within a study and are
caused by the same individuals contributing related data towards each outcome. In other words, within-study
correlation arises because of correlated patient outcomes within a trial, and between-trial correlation arises
because of correlated effects on the outcomes across studies.
Joint synthesis can improve efﬁciency over separate univariate syntheses (Riley et al., 2007a), can reduce
selective outcome reporting biases (Kirkham et al., 2012), and allows the association between outcomes to be
modelled, enabling joint inferences across outcomes and the prediction of one outcome from another, such as
a surrogate outcome. However, a major stumbling block is the availability of within-study correlations, which
are rarely provided in published reports. Methods and approaches have been suggested to deal with this problem
(Jackson et al., 2011; Berkey et al., 1996; Riley et al., 2008a; Riley, 2009; Nam et al., 2003). However, the availability of
individual participant data (IPD) from studies allows the within-study correlation to be directly calculated. Here, we
illustrate how to estimate these within-study correlations using IPD and show how their availability enables
multivariate meta-analysis to address clinically relevant questions about continuous, binary, survival and mixed
outcomes, across wide range of applications. Some of the approaches have been suggested previously, but others
are new. We focus mainly on a two-stage estimation framework (Simmonds et al., 2005; Riley et al., 2010), where
the effect estimates and their variances and correlations are obtained for the outcomes in each trial separately and
then synthesised in a multivariate model. The two-stage approach will be a familiar meta-analysis framework for
most readers. However, one-stage approaches may be preferable for more exact modelling of the likelihood
(Hamza et al., 2008; Trikalinos et al., 2013), estimating patient-level interactions (Riley et al., 2008b) and developing
prognostic models, and so, we also brieﬂy discuss one-stage approaches in sections 5 and 6 and the Discussion.
The article is structured as follows. Section 2 introduces a hypertension data set with multiple outcomes as
motivation. Section 3 describes the multivariate meta-analysis model in detail. Subsequent sections then describe
how to use IPD to produce multiple estimates in each study, along with their variances and correlations that then
allow the multivariate model to be applied. Section 4 considers multiple continuous outcomes and introduces the
idea of bootstrapping to estimate within-study correlations. Section 5 then considers binary, survival and mixed
outcomes. Section 6 highlights some speciﬁc and novel applications of multivariate meta-analysis, and ﬁnally,
section 7 concludes with discussion.2. Motivating example
The methods in this article are mainly illustrated through an IPD meta-analysis of hypertension trials. Wang et al.,
2005 investigated whether hypertension treatments lower SBP and DBP and whether they reduce the risks of a
subsequent diagnosis of cardiovascular disease (CVD) or stroke. They selected randomised controlled trials that
tested active anti-hypertensive drugs against placebo or no treatment, and IPD was sought from trials in the
INdividual Data ANalysis of Antihypertensive intervention trials (INDANA) data set (Gueyfﬁer et al., 1995) or at
the Studies Coordinating Centre in Leuven (Belgium) (Liu et al., 1998; Staessen et al., 1997; Amery et al., 1985).
Ten trials were ultimately included, providing IPD for a total of 28 581 patients (Table 1). The trials are summarised
in detail elsewhere (Riley et al., 2008b; Wang et al., 2005; Riley et al., 2013). The treatment and control groups were
well balanced in SBP and DBP in each trial at baseline (Riley et al., 2008b). A meta-analysis of the 10 trials is
important to summarise the effect of anti-hypertension drugs on (i) reducing SBP; (ii) reducing DBP; (iii) reducing
the risk of CVD; and (iv) reducing the risk of stroke. Speciﬁcally, we wish to examine the distribution of treatment
effects across the trials in order to estimate the average effects of anti-hypertension drugs on these four outcomes
and also to quantify the amount of between-trial variation in the outcome effects. It is also important to examine
how correlated the outcome effects are, for example, to ascertain whether treatment effectiveness on SBP is
correlated with treatment effect on DBP.3. Multivariate meta-analysis model
Before considering the use of IPD, we begin by introducing the general approach to multivariate meta-analysis
when results (in terms of effect estimates and their variances and correlations) for multiple outcomes are available
from a set of primary studies.3.1. General model
Let there be K outcomes of interest in a meta-analysis of N studies, and let θ^i be a vector containing the available K
effect estimates ((θ^ i1; θ^ i2;…; θ^ iK )) for the outcomes in the ith study (i=1 to N). The general speciﬁcation of the
multivariate meta-analysis model is© 2014 The Authors. Research Synthesis Methods published by John Wiley & Sons, Ltd. Res. Syn. Meth. 2015, 6 157–174
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0θ^ i jθieN θi; Sið Þ
θieN μ;Σð Þ (1)
Here, N denotes a multivariate normal distribution, θi contains the true underlying effects for the K outcomes
for the ith study, Si is the within-study variance–covariance matrix for the ith study (assumed ﬁxed and known)
containing the K variances of the effect estimates (in the diagonal: s2i1; s
2
i2;…; s
2
iK ) and their covariances (in the
off-diagonal; for example, ρWi(1,2)si1si2 is the within-study covariance for outcomes 1 and 2, where ρWi(1,2) is their
within-study correlation), μ contains the K average effects for the outcomes, and Σ is the between-study
variance–covariance matrix containing the K between-study variances of the true outcome effects (in the
diagonal: τ21; τ
2
2;…; τ
2
K ) and their between-study covariances (in the off-diagonal; e.g. the between-study
covariance for outcomes 1 and 2 is ρB(1,2)τ1τ2, where ρB(1,2) is their between-study correlation). The number of rows
in each vector is equal to the number of outcomes.
If some studies have missing outcome effect estimates (i.e. one or more of the entries of θ^ i1; θ^ i2;…; θ^ iK are
missing) then, assuming that these are missing at random and for computational convenience, such studies
can be incorporated by allocating them arbitrary values (e.g. set θ^ i1 = 0 if missing) with very large within-study
variances (e.g. set s2i1 = 1 000 000 if θ^ i1 is missing) and within-study correlations of 0. This replaces missing outcome
effects with estimates that have negligible weight and information during estimation.
We take Σ to be unstructured in this article, but simpliﬁcations are possible; for example, all between-study
correlations, or all between-study variances, could be assumed to be the same. Between-study correlations may be
increasingly difﬁcult to estimate as the number of outcomes increases, with frequentist estimates often at +1 or 1
when the number of studies is few, or the between-study heterogeneity is small relative to the within-study variability
(Riley et al., 2007b). Furthermore, in the presence ofmissing outcomes in some studies, theremust be enough estimated
effects, and combinations of these within studies, tomakeΣ identiﬁable. This is true for our applications throughout the
article. A multivariate ﬁxed effect model is obtained when Σ is 0, and model (1) is equivalent to two independent
univariate random-effect meta-analyses when all within and between-study correlations are assumed zero.
3.2. Estimation
Estimation of model (1) is needed to obtain estimates of μ and Σ. Estimation can be achieved by a variety of
options (Jackson et al., 2011), including restricted maximum likelihood (REML), method of moments (MM)
approaches (Jackson et al., 2010; Jackson et al., 2013; Chen et al., 2012), the U statistic (Ma and Mazumdar,
2011), and a Bayesian approach (Nam et al., 2003; Wei and Higgins, 2013a; Bujkiewicz et al., 2013). In this article,
we present results using REML and Bayesian estimation. REML does not by default account for the uncertainty
about Σ^ in the estimation of μ, but conﬁdence intervals (CIs) can be inﬂated to reﬂect the uncertainty (White,
2009; Jackson and Riley, 2014). After model estimation, multivariate extensions to I2 can be calculated (Jackson
et al., 2012), for each outcome separately and across both outcomes jointly. They express the fraction of variation
in the meta-analysis that is because of between-study heterogeneity rather than within-study sampling error.
For the Bayesian approach, prior distributions are necessary for μ and Σ. We give a vague separate normal prior
distribution for each component of μ, with a mean of zero and a large variance of 1 000 000. The prior distribution
is harder to specify for Σ, especially when there are three or more outcomes. The conjugate prior distribution for Σ
is an inverse Wishart distribution, but this is known to be potentially informative, and separation of the
components of Σ is preferred to allow realistically vague prior distributions on each term (Web Appendix 1)
(Wei and Higgins, 2013a; Barnard et al., 2000). Σ is ﬁrst separated into variance and correlation matrices by
Σ=V1/2RV1/2, where V1/2 is a diagonal matrix with between-study standard deviations as elements and R is the
k× k matrix of between-study correlations (where k is the total number of outcomes). Then, R is re-parameterised
to enforce positive-deﬁnite constraints. Cholesky decomposition or spherical decomposition can achieve this, and
we refer the reader to Wei and Higgins who describe this in full (Wei and Higgins, 2013a). Our WinBUGS code for a
four outcome multivariate meta-analysis using either decomposition is given in Web Appendix 1. A product-
normal speciﬁcation of Σ is also possible (Spiegelhalter et al., 2000; Bujkiewicz et al., 2013).
In the bivariate setting, an example set of prior distributions is
μ1 e N 0; 1000000ð Þ μ2 e N 0; 1000000ð Þ
τ1 e N 0; 1ð ÞI 0ð Þ τ2 e N 0; 1ð ÞI 0ð Þ
ρB 1;2ð Þ e Uniform 1; 1ð Þ
where ρB(1,2) is the between-study correlation of θi1 and θi2. WinBUGS code for the bivariate setting is given in Web
Appendix 2. In situations where vague prior distributions are required, we suggest that a number of prior
distributions are examined, especially when the number of studies is small, as the choice of prior distributions
for τ1, τ2 and ρB(1,2) may affect the posterior results (Lambert et al., 2005). Of course, external evidence regarding
τ1, τ2 and ρB(1,2) can be incorporated in the prior distributions where available. For example, if ρB(1,2) is considered
positive, then its prior distribution could be chosen to allow only positive values.© 2014 The Authors. Research Synthesis Methods published by John Wiley & Sons, Ltd. Res. Syn. Meth. 2015, 6 157–174
R. D. RILEY ET AL.3.3. Advantages over univariate meta-analysis
Model (1) is particularly advantageous over separate univariate meta-analyses of each outcome when some outcomes
are systematically missing (i.e. only one of the outcomes is available) in some of the studies (Riley et al., 2007a) or when
inferences are to bemade jointly about the average effects of two ormore outcomes (e.g. μ1 and μ2) (Thompson et al.,
2005) or jointly about the predicted outcome effects (e.g. θi1 and θi2) in a new population (Buyse et al., 2000). Such
predictions are perhaps most suited to the Bayesian framework, in particular to propagate the uncertainty in Σ^
and allow direct probability statements about the magnitude of effects for both outcomes. Web Appendices 2
and 3 gives examples of calculating such probability statements from a Bayesian analysis.1
6
14. Multivariate IPD meta-analysis of continuous outcomes
Here onwards, we concentrate on facilitating the multivariate model (1) by using IPD to obtain the necessary
effect estimates, and their within-study variances and covariances, from each study. We begin by considering
multiple continuous outcomes, such as SBP and DBP, when given IPD from N randomised trials. In the ﬁrst stage,
each of these studies is analysed separately, and then in the second stage, model (1) is applied, as now described.
4.1. First stage
Assume that there is a treatment group (T) and a control group (C) in each trial and that two continuous outcomes
(k= 1 or 2) are of interest. At baseline (i.e. before randomisation), the jth patient in the ith trial provides their SBP
and DBP values, which we denote by yBijk, where B indicates baseline and k=1 for SBP and k= 2 for DBP. Also, each
patient provides their ﬁnal SBP and DBP values after treatment, which we denote by yFijk (where F indicates ﬁnal).
Let xij be 0/1 for patients in the control/treatment group respectively. When such data are available, the ﬁrst step
of a two-step IPD multivariate meta-analysis must estimate the treatment effects for each outcome in each trial.
4.1.1. Option 1: modelling outcomes separately within each trial. The most appropriate linear regression model to
use in this situation is analysis of covariance (ANCOVA) (Riley et al., 2013), where the outcome follow-up value is
the response variable and the treatment effect is estimated adjusted for the baseline value. For each outcome and
each trial separately, the ANCOVA model to be ﬁtted is
yFijk ¼ ϕik þ βikyBijk þ θikxij þ eijk
eijk e N 0; σ2ik  (2)
In this model, ϕik is the ﬁxed trial effect for outcome k, βik denotes the mean change in yFijk for a one-unit
increase in yBijk, θik is the underlying treatment effect for outcome k in trial i, and σ2ik is the residual variance of
outcome k in trial i after accounting for treatment and baseline values. The model is simply a linear regression
and so can easily be estimated in standard statistical software. From this, the treatment effect estimate, θ^ ik , and
its variance, s2ik , are obtained for each outcome in each trial. If baseline values are unavailable, then model
(2) excluding the baseline value as a covariate will still give unbiased θ^ ik when patients are randomised to
the treatment groups, although θ^ ik will be less efﬁcient.
4.1.2. Option 2: modelling outcomes jointly within each trial. Model (2) can be applied to each outcome
separately, but for continuous outcomes, one can simultaneously ﬁt model (2) for both outcomes as follows:
yFijk ¼ φik þ βikyBijk þ θikxij þ eijk
eijk e N 0; σ2ik 
cov eij1; eij2
  ¼ σ i12 (3)
In this framework, each patient now contributes two follow-up responses and two baseline values (one for each
outcome) to a single model containing both outcomes jointly (Riley et al., 2008b). It is thus similar to a repeated
measure model, and the correlation in patient outcome responses is accounted for by the covariance term, σi12.
For estimation purposes, it is helpful to re-write model (3) with dummy variables as shown in Web Appendix 3,
with associated SAS code. When each patient provides both outcomes, then model (3) will give approximately
the same treatment effect estimates and standard errors as obtained from ﬁtting model (2) to each outcome
separately. However, model (3) can also include patients with one of the outcomes missing and, under a missing
at random assumption, will utilise the patient-level correlation to ‘borrow strength’ across outcomes. In situations
with a large proportion of incomplete outcome data (i.e. only one outcome observed), this extra information may
lead to different treatment effect estimates with lower variances than from model (2). Such a scenario is unlikely in
well-designed prospective studies such as randomised trials.© 2014 The Authors. Research Synthesis Methods published by John Wiley & Sons, Ltd. Res. Syn. Meth. 2015, 6 157–174
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24.1.3. Estimating within-study correlations directly or via bootstrapping. An important part of a multivariate meta-
analysis is to estimate and utilise the within-study correlations between the outcome effect estimates. For
example, consider two outcomes (such as SBP and DBP), and let the within-study correlation of θ^ i1 and θ^ i2 in trial
i be denoted by ρWi(1,2), where
ρWi 1;2ð Þ ¼
cov θ^ i1; θ^ i2
 
si1si2
¼ si 1;2ð Þ
si1si2
(4)
Model (3) models the covariance between the patient outcome responses, and this naturally induces a within-
study correlation (ρWi(1,2)) between the estimated treatment effects, θ^ i1 and θ^ i2. After estimation of model (3),
ρWi(1,2) is therefore calculable directly using the variances, s2i1 and s
2
i2, and the covariance, si(1,2), available from
the inverse of Fisher’s information matrix. Statistical software such as SAS (Web Appendix 3) provides these
results upon request.
Model (2), however, does not model patient-level correlation and analyses each outcome separately; therefore,
the within-study correlations are not estimated. However, they can be estimated via non-parametric
bootstrapping. This approach randomly selects one patient with replacement, then randomly selects a second
patient with replacement, and repeats until the same sample size is obtained as in the trial. This process is
repeated b times so that b bootstrap samples are obtained. Then, in each of the bootstrap samples, model (2)
is ﬁtted to outcome 1 (e.g. SBP) to obtain θ^ i1 and then to outcome 2 (e.g. DBP) to obtain θ^ i2. This produces b values
of θ^ i1 and θ^ i2, and their observed correlation can be calculated, which gives ρWi(1,2). When b is large, the ρWi(1,2)
estimated from bootstrapping should be very similar to the ρWi(1,2) estimated directly from model (3) (this is
demonstrated in section 4.3 and Table 1).
4.2. Second stage
The ﬁrst stage therefore provides treatment effect estimates (θ^ ik) and their variances (s2ik), for each outcome in each
trial, and their within-study correlations (e.g. ρWi(1,2)). Multivariate model (1) can now be implemented. For
example, if there are two outcomes, then model (1) becomes a bivariate random-effect meta-analysis, which
written in full is (Van Houwelingen et al., 2002; Jackson et al., 2011)
θ^ i1
θ^ i2
 !
e N θi1θi2
 !
; Si
 !
Si ¼
s2i1 ρWi 1;2ð Þsi1si2
ρWi 1;2ð Þsi1si2 s
2
i2
0@ 1A
θi1
θi2
 !
e N μ1μ2
 !
;Σ
 !
Σ ¼
τ21 ρB 1;2ð Þτ1τ2
ρB 1;2ð Þτ1τ2 τ22
0@ 1A (5)
4.3. Application to the hypertension data
4.3.1. Within-study correlations. The joint ANCOVA model (3) was applied to each of the hypertension trials
separately, to estimate the treatment effect on SBP and DBP after adjusting for baseline values. The
treatment effect estimates and their variances for SBP and DBP are shown in Table 1, together with their
within-study correlations that are all positive and quite high (ranging from 0.45 to 0.79). They are shown
visually through the direction of the conﬁdence ellipse for the effects in each trial (Figure 1). Therefore,
there is a strong association between the treatment effect estimates for SBP and DBP, a consequence of
the high correlation between SBP and DBP values in individuals, and this justiﬁes why consideration of
correlation is important. The within-study correlations estimated via model (2) with bootstrapping were very
similar (Table 1).
4.3.2. Between-study correlation. The trial treatment effect estimates were combined in a bivariate meta-analysis
model (5), using within-study correlations estimated via bootstrapping. The frequentist results after REML
estimation are shown in Table 2. Bayesian analyses led to similar conclusions and are thus not presented in full
here; however, the WinBUGS code to replicate the analysis is shown in Web Appendix 2. REML estimates a high
positive between-study correlation of 0.78, indicating that trials with a higher than average true treatment effect
on SBP also have a higher than average true treatment effect on DBP. This can be seen visually in Figure 1 by
looking at the relationship across trials. Thus, if for some reason the treatment effect on DBP was not observed
in a trial, one might use the high between-study correlation to predict the effect on DBP from the observed effect
on SBP.
4.3.3. Summary treatment effects. The REML summary treatment effect estimates indicate that, on average,
hypertension treatment reduces both SBP (μ^1 =10.21, 95% CI: 12.11 to 8.30) and DBP (μ^2 =4.59, 95% CI:© 2014 The Authors. Research Synthesis Methods published by John Wiley & Sons, Ltd. Res. Syn. Meth. 2015, 6 157–174
-
10
-
8
-
6
-
4
-
2
0
Tr
ea
tm
e
n
t e
ffe
ct
 
on
 
D
BP
-20 -15 -10 -5 0
Treatment effect on SBP
50% confidence region
Probability* of 
0.34 that the 
true treatment 
effects for SBP 
& DBP in a new 
study will both
fall in this region 
Figure 1. Relationship between the treatment effect estimates on systolic blood pressure (SBP) and diastolic blood pressure (DBP), within and
across trials. The crosses indicate a pair of estimates from one trial, and the angle of the conﬁdence ellipse around each estimate indicates the
within-study correlation. The solid circle denotes the pair of summary estimates from the meta-analysis, and the circle around it denotes its
conﬁdence ellipse. 50% (rather than 95%) conﬁdence ellipses are given for cosmetic reasons, as otherwise the regions are large and overlap
considerably. * estimated from a Bayesian bivariate meta-analysis model, with prior distributions as speciﬁed in section 3.2. This is the proportion
of the joint posterior distribution for the underlying treatment effects of these two outcomes that falls within this region.
Table 2. Bivariate and multivariate meta-analysis results for the hypertension data as obtained from REML
estimation
Model Outcome Effect type
Summary
treatment
effect
95% CI for the
summary
effect^
Between-study
standard
deviation(s)*
Between-study
correlation(s)
Bivariatea SBP Mean difference 10.21 12.11 to 8.30 2.71 SBP, DBP 0.78
DBP Mean difference 4.59 5.61 to 3.57 1.48
Bivariate SBP ≤ 120 Odds ratio 2.45 1.96 to 3.06 0.119 SBP, DBP 0.35
DBP ≤ 80 Odds ratio 2.34 2.01 to 2.72 0.204
Bivariate CVD HR 0.78 0.69 to 0.89 <0.000001 CVD, stroke 1.00**
Stroke HR 0.68 0.60 to 0.78 <0.000001
Multivariate SBP Mean difference 10.22 12.14 to 8.30 2.73 SBP, DBP 0.79
SBP, CVD 0.31DBP Mean difference 4.63 5.67 to 3.60 1.51
SBP, stroke 0.53CVD HR 0.79 0.69 to 0.91 0.05
DBP, CVD 0.83Stroke HR 0.73 0.61 to 0.87 0.14
DBP, stroke 0.94
CVD, stroke 0.97
aThese results correct those bivariate REML results displayed elsewhere that used slightly different trial estimates
and variances for this hypertension data (Riley et al., 2008b; Jackson et al., 2013).
^Inﬂated to account for uncertainty in the estimation of between-study standard deviation and correlation.
*Measured on the log HR scale for stroke and CVD and on log OR scale for SBP ≤ 120 and DBP≤ 80.
**Estimation at edge of boundary space is a consequence of between-study standard deviation estimates close
to zero.
R. D. RILEY ET AL.5.61 to 3.57) by more than placebo. The Bayesian approach obtains similar estimates and gives a posterior
probability of almost 1 that μ1< 0 and a probability almost 1 that μ2< 0, providing very strong evidence that
treatment is effective at reducing each outcome. One can also make joint inferences. For example, there is a
probability of 0.12 that treatment will reduce both SBP and DBP by at least 5mmHg on average, which illustrates
the use of a more stringent minimum reduction for clinical acceptability. One might also be interested in the
average treatment effect on pulse pressure (SBPDBP), which is μ^1  μ^2 = 5.61 (95% CI: 6.94 to 4.29) using
the REML estimates. We note that ignoring the correlation between μ^1 and μ^2 produces a more conservative CI
of 7.73 to 3.42.1
6
34.3.4. Predicted treatment effects in a new population. There is heterogeneity in treatment effect across trials
(τ^1 = 2.71, τ^2 = 1.48 from REML estimation), potentially caused by differences in patient-level and study-level
characteristics. Given the heterogeneity, clinicians might not be interested in the average treatment effect© 2014 The Authors. Research Synthesis Methods published by John Wiley & Sons, Ltd. Res. Syn. Meth. 2015, 6 157–174
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4across trials but rather the predicted treatment effect (θnew1 and θnew2) when it is implemented in a new
population. Interest then lies in the bivariate distribution of θnew1 and θnew2 for a new study, that is, the
joint distribution of true treatment effects across new studies for the two outcomes. The Bayesian approach
gives a 95% prediction interval of 14.11 to 5.82 for the treatment effect on SBP and 7.28 to 1.75 for
the treatment effect on DBP. These intervals account for the uncertainty in μ^1 , μ^2 , and Σ^ . There is a
probability of 0.99 that treatment will reduce both SBP and DBP more than placebo in a new population.
Further, there is a probability of 0.34 that the treatment will reduce both SBP and DBP by at least 5mmHg
more than placebo in a new population. This is the probability that the two predicted effects will fall in the
marked area of Figure 1.5. Multivariate IPD meta-analysis for binary, survival and mixed outcomes
We now extend the two-stage framework of section 4 to consider binary, survival, and mixed outcomes.5.1. Binary outcomes
Often, researchers are interested in multiple binary outcomes, and these may also be related to one
another, especially if they are nested or mutually exclusive. Nested outcomes occur when one outcome is
a subset of the other, such as unplanned caesarean section and any adverse maternal outcome in pregnancy.
Mutually exclusive outcomes occur when patients with one outcome cannot experience the other, for
example, delivery by caesarean section and instrumental delivery other than caesarean section. In each trial,
within IPD, those nested or mutually exclusive binary outcomes can be identiﬁed, and the number of events
obtained for each (although, such information may also be available in study publications, for example, in
contingency tables). Treatment effect estimates such as of log odds ratios (ORs) or log relative risks can then
be estimated for each outcome in each study, along with their within-study variances. Their within-study
correlations can be estimated by the formulae provided by Trikalinos and Olkin, 2008 for mutually exclusive
outcomes and Wei and Higgins, 2013b for nested outcomes. Then, multivariate meta-analysis model (1) can
be applied.
Multivariate meta-analysis model (1) can also be used to jointly synthesise effects for related binary outcomes
that are neither nested nor mutually exclusive, such as pain-free walk by 1month and reduction in swelling by
1month after a knee operation. Wei and Higgins, 2013b provide formulae for calculating within-study correlations
for treatment effects for these outcomes, which requires an estimate of the patient-level correlation of outcome
responses, which could easily be derived with the IPD.
It is also straightforward to implement the bootstrap procedure described in section 4.1.3 to estimate
their within-study correlation. For example, one can ﬁt to each trial and each outcome separately a logistic
regression model:
ln
pijk
1 pijk
 !
¼ αik þ θikxij (6)
where pijk is the probability of patient j in study i experiencing outcome k, and αik is the log odds of
outcome k in study i for the control group, xij is 1 for those in the treatment group and 0 for control
group, and θik denotes the log OR (i.e. the treatment effect) in the ith study for outcome k. The model
can be estimated by maximum likelihood, to give the treatment effect estimate θ^ ik and its variance s2ik
for each outcome in each trial. Baseline covariates might also be included alongside xij in order to
increase power or adjust for baseline confounding. To estimate the within-study correlations, the
bootstrap is then used, where now, logistic regression model (6) is applied to each of the b bootstrap
samples, producing b pairs of log OR estimates for each pair of outcomes and thereby enabling their
correlation to be estimated.
Within-study correlations do not need to be derived if, rather than a two-stage framework, a one-stage
multivariate meta-analysis is rather performed. For example, for nested or mutually exclusive outcomes,
Trikalinos et al., 2014 show how multinomial distributions can be used to model the number of events
within studies whilst incorporating random effects to allow for between-study heterogeneity and correlation
in the true log ORs. The use of discrete within-study likelihoods in this way avoids the (potentially
inappropriate) large sample normality assumption of the log OR estimates in each study and avoids
the need for continuity correlations (Stijnen et al., 2010). However, in our experience, such one-stage
meta-analyses can sometimes lead to convergence problems (Riley et al., 2007b), especially when trying
to accommodating studies with missing outcomes, and thus, the two-stage approach may often be
more practical.© 2014 The Authors. Research Synthesis Methods published by John Wiley & Sons, Ltd. Res. Syn. Meth. 2015, 6 157–174
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55.1.1. Application to the hypertension data. Clinicians typically deﬁne a normal SBP as ≤120mmHg and a normal
DBP as ≤80mmHg. We now consider these as two binary outcomes and evaluate whether hypertensive treatment
improves the odds of having a normal SBP and DBP by the end of the trial. Model (6) was applied to each outcome
in each study, to obtain the treatment effect estimates and their variances (data shown in Web Appendix 4).
Bootstrapping estimated positive within-study correlations, ranging from +0.05 to +0.48. Multivariate
meta-analysis model (1) was then applied using REML, and the summary results show that, compared with
control, hypertension treatment improves the odds of having a normal SBP and DBP (Table 2). Interestingly,
the summary result and 95% CI for DBP are similar whether univariate or multivariate meta-analysis is
applied (OR = 2.34, 95% CI: 2.01 to 2.72). However, for SBP, the summary result has a wider CI in the
multivariate (OR = 2.45, 95% CI: 1.96 to 3.06) compared with univariate (OR = 2.46, 95% CI: 2.19 to 2.76)
meta-analysis, as a result of a larger estimate of between-study standard deviation (0.12 vs 0.043). This
highlights how multivariate meta-analysis also borrows strength across outcomes for the estimates of
heterogeneity. The treatment effect estimates for SBP have large variances in some trials, as a result of only
a few patients obtaining a normal SBP. This imbalance in SBP variances across studies improves the
opportunity to borrow strength (Riley et al., 2007a) from the treatment effect estimates for DBP, which have
consistently smaller variances (Web Appendix 4), via the within-study correlations and between-study
correlation of +0.35.
5.2. Survival outcomes
Often, researchers are interested in a treatment effect on multiple time-to-event (survival) outcomes, for
example, the time to disease recurrence and the time to death. These may also be correlated, and thus,
multivariate meta-analysis is again appealing. For simplicity in this paper, we assume that a Cox
proportional hazard model is appropriate for all time-to-event outcomes. However, we recognise that with
IPD, more sophisticated multivariate survival models (Wassell and Moeschberger, 1993; Hougaard, 2000;
Burzykowski et al., 2001; Michiels et al., 2009), multistate modelling (Putter et al., 2007; Price et al., 2011),
and one-stage meta-analyses (Crowther et al., 2012; Rondeau et al., 2011) are possible, and outcomes with
competing risks can be synthesised using more sophisticated analyses (Ades et al., 2010). We do not have
space to consider such topics in sufﬁcient detail here and so focus our attention on facilitating multivariate
meta-analysis using standard approaches. Therefore, in the event of death, other outcomes that have not
occurred are censored at the death time.
Given IPD, one can ﬁt to each trial and each outcome separately a Cox model (Cox, 1972)
hijk tð Þ ¼ h0ik tð Þ exp θikxij
 
(7)
where hijk(t) is the hazard function over time t for having an outcome k event for the jth individual in the
ith trial. Each trial has its own baseline hazard (h0ik(t)), which denotes the hazard of an event in the control
group for outcome k, and the parameter θik denotes the log hazard ratio (i.e. the treatment effect) in the
ith study for outcome k. The model can be estimated by numerical maximisation of the partial likelihood
(Cox, 1972), to give the treatment effect estimate θ^ ik and its variance s2ik for each outcome in each trial.
Baseline covariates might also be included alongside xij in order to increase power. A method for handling
tied failure times in the calculation of the log partial likelihood may also be required; here, we use the
Breslow method (Breslow, 1975).
Applying model (7) to each outcome separately does not provide the within-study correlations between
the multiple θ^ iks of interest. However, as described for the logistic regression models for binary outcomes,
they can be estimated using the bootstrapping procedure described in section 4.1.3. This is also
highlighted elsewhere (Bujkiewicz et al., 2013). Once estimated, the multivariate meta-analysis model (1)
can then be ﬁtted.
5.2.1. Application to the hypertension data. Consider the two outcomes of CVD and stroke. Model (7) was used in
each trial to estimate the treatment effect on CVD incidence rate and then again to estimate the treatment effect
on stroke incidence rate. Bootstrapping was used to estimate the within-study correlations, and these are all
positive and often high (ranging from 0.10 to 0.78) (Table 1). This suggests an underlying strong positive
association at the individual level between reduction in stroke incidence and reduction in CVD incidence from
using the treatment. This is expected, as stroke is one of the main reasons for a diagnosis of CVD (others include
angina, heart attack, and heart failure).
Estimation of bivariate meta-analysis model (5) using REML gives a between-study correlation of +1
(Table 2); however, this is poorly estimated and has very little impact on the summary results because both
between-study variances are estimated to be almost zero. Thus, the results are similar to those from a
bivariate ﬁxed effect meta-analysis, and the lack of heterogeneity suggests that the effect of treatment
may be consistent across populations. The summary hazard ratios less than 1 indicate that hypertension
treatment is effective at reducing both stroke and CVD risk (Table 2). In comparison to univariate meta-© 2014 The Authors. Research Synthesis Methods published by John Wiley & Sons, Ltd. Res. Syn. Meth. 2015, 6 157–174
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6analyses, the large within-study correlations allow borrowing of strength across outcomes, and this produces
slightly narrower CIs as a result of smaller standard errors. For example, for stroke, the standard error of the
summary log hazard ratio is reduced from 0.074 in the univariate analysis to 0.070 in the bivariate analysis, a
reduction of about 5%. Joint inferences can also be made accounting for the correlation. For example,
following a bivariate Bayesian analysis, the estimated probability that hypertension treatment will reduce
the hazard of stroke and CVD by at least 20% in a new study is 0.52. If one wrongly ignores the correlation
between outcomes, the estimated probability is lower at 0.47. In situations where different treatment
options are being compared (e.g. when multiple treatments exist for the same disease or when resource
limits the number of treatments that can be purchased by a particular health care body), such discrepancies
in the estimated probability of success may impact upon the priority ranking of each treatment (refer to
Network meta-analysis, section 6.5).5.3. Mixed outcomes
So far, we have considered multivariate meta-analysis for multiple outcomes of the same type. However,
multivariate meta-analysis can also be applied for mixed outcomes, For example, in the hypertension example,
the treatment effects on the continuous outcomes of SBP and DBP can be considered jointly with the treatment
effects on the survival outcomes of stroke and CVD. The availability of IPD allows within-study correlations
between these mixed outcomes to be estimated, with bootstrapping again a convenient approach. Here, in the
b bootstrap samples for each study, different types of analyses can be ﬁtted to each outcome: for example, an
ANCOVA for SBP, an ANCOVA for DBP, a Cox regression for CVD, and a Cox regression for stroke. These provide
b sets of treatment effect estimates, and their correlations give the within-study correlations. Example STATA code
is provided in Web Appendix 5 to do this.5.3.1. Application to the hypertension dataset. The REML results for the multivariate meta-analysis of all four
outcomes (SBP, DBP, stroke and CVD) show that hypertension treatment is effective for all four outcomes on
average, with the summary effect for SBP and DBP <0 and the summary hazard ratio for stroke and CVD <1
(Table 2; NB the summary hazard ratios are the exponential of the summary loge hazard ratio estimates from
the multivariate model). Bayesian estimates were very similar (available on request). Interestingly, after
accounting for the between-study correlations with SBP and DBP, the multivariate model (1) provides larger
estimates of between-study heterogeneity for both stroke and CVD (compared with the bivariate results in
section 4.4.1). This is because of the borrowing of strength across outcomes for the average effects and the
heterogeneity, as mentioned previously.
The multivariate approach allows joint probability statements across the mixed outcomes. For example, the
Bayesian multivariate meta-analysis estimates that, if applied to a new population, the probability that
hypertension treatment will reduce SBP by at least 5mmHg and reduce the hazard of stroke by at least 20% is
0.82. This is illustrated by the probability of the effects falling in the shaded area of Figure 2.-
3
-
2
-
1
0
1
2
Tr
ea
tm
e
n
t e
ffe
ct
 
on
 
st
ro
ke
 
(lo
gH
R)
-20 -15 -10 -5
Treatment effect on SBP (mmHg)
50% confidence region
Probability* of 0.82 that 
the true treatment 
effects for SBP & stroke 
in a new study will both
fall within this clinically 
important region 
Figure 2. Relationship between the treatment effect estimates on systolic blood pressure (SBP) and stroke, within and across trials. The crosses
indicate a pair of estimates from one trial, and the angle of the conﬁdence ellipse around each estimate indicates the within-study correlation. The
solid circle denotes the pair of summary estimates from the meta-analysis, and the circle around it denotes its conﬁdence ellipse. 50% (rather than
95%) conﬁdence ellipses are given for cosmetic reasons, as otherwise the regions are large and overlap considerably. * estimated from a Bayesian
four-outcome multivariate meta-analysis model, with prior distributions as speciﬁed in section 3.2 and Web Appendix 1. This is the proportion of the
joint posterior distribution for the underlying treatment effects of these two outcomes that falls within this region.
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76. Special applications of multivariate meta-analysis
So far, we have considered multivariate meta-analysis to jointly estimate treatment effects on several outcomes.
We now consider some different applications where IPD multivariate meta-analysis might be useful.
6.1. Treatment–covariate interactions
Clinicians often want to know how treatment effect is modiﬁed by clinical and patient characteristics, such as age,
sex or biomarker levels. It may therefore be important to extend the models in previous sections to include
patient-level covariates and estimate treatment–covariate interactions.
Assume that IPD are available from all trials and there is just one outcome of interest. Let zij be a patient-level
covariate (e.g. the age of patient j in trial i), which is observed for all patients in each trial. Simmonds and Higgins,
2007 suggest a two-step method for estimating the treatment–covariate interaction, and we extend their
approach here, focusing on one continuous outcome. As in section 4, the ﬁrst stage involves ﬁtting a model to
the IPD from each trial separately, akin to model (2) but here for just one outcome and with an interaction term
(Riley et al., 2008b; Higgins et al., 2001):
yFij ¼ φi þ βiyBij þ θixij þ ζ i zij þ γWi xijzij þ εij
εij e N 0; σ2i  (8)
The parameters are as explained under model (2) with now θi the treatment effect for those patients with zij= 0; ζ i
is the effect of a one-unit increase of covariate zij on blood pressure outcome (yFij); and γWi is the change in
treatment effect for a one-unit increase in zij. In other words, γWi is the within-trial treatment–covariate interaction,
using language consistent with articles on interaction estimates elsewhere (Riley et al., 2008b; Riley and
Steyerberg, 2010). When ﬁtted to each trial’s IPD, the model produces an interaction estimate, γ^Wi, and its variance,
V(γ^Wi ), for each trial. These can be synthesised across trials in a standard univariate meta-analysis model (Riley
et al., 2008b; Simmonds and Higgins, 2007), such as a random-effect model:
γ^Wi e N γWi;V γ^Wið Þð Þ
γWi e N μγW ; τ2γW  (9)
V(^γWi) is assumed known, and the model provides a summary estimate of the within-trial treatment–covariate
interaction, μγW , and the between-trial heterogeneity in the interaction (τ
2
γW
).
If the covariate zij is binary (let us say, 1 for males and 0 for females), then μγW gives the mean change in
treatment effect for males compared with females. However, along with this contrast, it may also be informative
to know the summary treatment effects for males and females separately. Therefore, as an alternative to model
(9), one might ﬁt the following bivariate meta-analysis to the treatment effect estimates for females (θ^ i) and males
(θ^ i + γ^Wi) and their variances V(θ^ i) and V(θ^ i + γ^Wi):
θ^ i þ γ^Wi
θ^ i
 !
e N μδμθ
 !
; Si þΩ
 !
Si ¼
V θ^ i þ γ^Wi
 
ρWi 1;2ð Þ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
V θ^ i þ γ^Wi
 
V θ^ i
 r
ρWi 1;2ð Þ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
V θ^ i þ γ^Wi
 
V θ^ i
 r
V θ^ i
 
0BBB@
1CCCA
Ω ¼
τ2δ ρB 1;2ð Þτδτθ
ρB 1;2ð Þτδτθ τ2θ
0@ 1A
(10)
As before, the within-study variances (V(ðθ^ i þ γ^Wi) and V(θ^ i)) are assumed known. Generally, the within-study
correlation (ρWi(1,2)) will be close to zero; males and females are different sets of individuals, but their treatment effects
share a common adjustment for baseline values in model (8), which induces some correlation. Estimation of model (10)
provides the summary treatment effect for males (μ^δ), the summary treatment effect for females (μ^θ), and the between-
study variances (^τ2γ and τ^
2
θ) and between-study correlation (ρ^B 1;2ð Þ). The between-study correlation arises as studies with
a larger true treatment effect for males may be associated with a larger (or smaller) treatment effect for females.
After ﬁtting model (10), the summary interaction (difference in treatment effect for males and females) can be
estimated by μ^γ= μ^δ  μ^θ, with its variance = var(μ^δ) + var(μ^θ) 2cov(μ^δ, μ^θ). However, μ^γ is no longer purely based
on within-trial information (and hence why we have removed the ‘W’ term here) and rather is an amalgamation of
the within-trial interactions (e.g. difference in treatment response between males and females in the same trial)
and between-trial interaction (e.g. difference in mean treatment effect from a study with all males compared with
a study with all females) (Riley et al., 2008b; Riley and Steyerberg, 2010; Thompson et al., 2010). To understand this,
it is helpful to consider a study that only provides the treatment effect for females. This study can be included© 2014 The Authors. Research Synthesis Methods published by John Wiley & Sons, Ltd. Res. Syn. Meth. 2015, 6 157–174
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8within the bivariate model (10) and would impact upon μ^θ and therefore also upon μ^γ = μ^δ  μ^θ . Thus, the
summary interaction estimate is inﬂuenced by a study that provides no estimate of within-trial interaction.
It can be shown that μ^γ will be based solely on the between-trial interaction when trials only contain either males or
females (i.e. when the within-trial interactions are not observable). Conversely, μ^γ will be based solely on within-trial
informationwhen the proportion ofmales is the same in each trial (i.e. when between-trial interaction is not observable)
(Simmonds and Higgins, 2007; Simmonds, 2005). Most IPD meta-analysis situations will be somewhere in between.
Some authors (e.g. (Riley et al., 2008b; Riley and Steyerberg, 2010; Thompson et al., 2010; Sutton et al., 2008;
Jackson et al., 2006)) propose using μ^γ (and thus combining within-trial and across-trial interactions) to gain power,
especially when not all trials provide IPD. The use of μ^γ is particularly appealing when the between-trial information
has large precision (Simmonds and Higgins, 2007), as a result of large variation in covariate means across trials (an
extreme example is when some trials contain only females and other trials only males). However, this approach
implicitly assumes that the between-trial and within-trial interactions are the same. This is a strong assumption, as
it is known that between-trial relationships are more prone to confounding and ecological bias. Many examples
of this problem have been shown (Riley et al., 2008b; Riley and Steyerberg, 2010; Simmonds, 2005; Berlin et al., 2002).
For continuous covariates, model (10) is not appropriate as there are no longer two subgroups. However, an
alternative is a bivariate meta-analysis with θ^ i (the treatment effect estimate for that with a zero covariate value)
and γ^Wi (the change in treatment effect for a one-unit increase in the covariate), the two responses of interest. By
accounting for within-study and between-study correlations, estimation of the bivariate model will give a
summary interaction estimate that again combines the within-trial and between-trial interactions (Riley et al.,
2008b; Riley and Steyerberg, 2010).6.1.1. Application to the hypertension data. Model (8) was applied to each trial in the hypertension data, with sex
as a covariate and SBP as the outcome of interest. This produces the within-trial interaction estimate (^γWi) and the
treatment effect estimate for females ( θ^ i ) for each trial, their variances (V( γ^Wi ) and V( θ^ i )), and within-study
correlations (ρWi(1,2)), which are close to zero. REML estimation of model (9) gave a summary within-trial interaction
of μ^γW = 0.93 (95% CI: 0.32 to 2.17; τ^ θ = 1.23)). Thus, there is no evidence of an overall difference in treatment
effect between males and females.
REML estimation of the bivariate model (10) gave a high summary treatment effect for females (μ^θ =10.66;
95% CI: 12.76 to 8.55; τ^ θ = 2.94)) and a high summary treatment effect for males (μ^δ =9.37; 95% CI: 11.11
to 7.63)). The estimated between-study correlation was large (ρB=0.86), indicating that populations with a larger
treatment effect for males also have a larger treatment effect for females.
The summary interaction estimate from model (10) is μ^γ= μ^δ  μ^θ =1.28 (95% CI: 0.23 to 2.80). This summary
interaction combines the within-trial and between-trial interactions. It is noticeably larger than that based solely
on within-trial information (1.28 vs 0.93) and has a wider CI as a result of larger estimates of the between-study
variances in the bivariate model. Thus, the use of between-trial information is providing additional information
here, although it may also be inducing ecological bias and study-level confounding. Nevertheless, all summary
interaction estimates provide no evidence of a difference in treatment effect for males compared with females.6.2. Prognostic or risk factor studies: combining partially and fully adjusted results
A major advantage of IPD is the ability to adjust for confounders and prognostic variables. This allows adjustment
for baseline imbalance in randomised trials and can improve statistical power. In prognostic (or risk) factor studies,
it also allows adjusted prognostic associations to be estimated, to reveal whether a novel factor retains its
prognostic value after adjusting for existing prognostic factors. Nevertheless, even with IPD, some studies may
not provide the adjustment variables of interest. In this setting, The Fibrinogen Studies Collaboration (The
Fibrinogen Studies Collaboration, 2009) used a bivariate meta-analysis to account for the correlation between
partially (P) adjusted and fully (F) adjusted prognostic factor effects, to borrow strength from partially adjusted
effect estimates (θ^ iP) in studies where fully adjusted effect estimates (θ^ iF) are unavailable. The model is as follows,
and for full details, refer to The Fibrinogen Studies Collaboration, 2009:
θ^ iP
θ^ iF
 !
e N θiPθiF
 !
; δi
 !
δi ¼
s2iP ρWi P;Fð ÞsiPsiF
ρWi P;Fð ÞsiPsiF s2iF
0@ 1A
θiP
θiF
 !
e N μPμF
 !
;Ω
 !
Ω ¼
τ2P τPτFρB
τPτFρB τ
2
F
 ! (11)
The siP and siF are the standard errors of θ^ iP and θ^ iF , respectively. Bootstrapping can estimate the within-study
correlations (ρWi(P,F)) between partially and fully adjusted results in those studies that provide both (The Fibrinogen
Studies Collaboration, 2009), as described in the preceding texts and shown in Web Appendix 5. A similar idea© 2014 The Authors. Research Synthesis Methods published by John Wiley & Sons, Ltd. Res. Syn. Meth. 2015, 6 157–174
R. D. RILEY ET AL.
1
6
9to utilise correlations to borrow strength is considered by others (Greenland, 1987; Steyerberg et al., 2000;
Debray et al., 2012).
6.2.1. Application to the hypertension data. As an illustration, assume that the ﬁrst ﬁve trials in Table 1 provide IPD
with treatment group, smoking, age and BMI available for all patients; however, the last ﬁve trials only provide IPD
with smoking and treatment group. We now ask a new question: Is smoking a prognostic factor for stroke? Thus,
the trials are now observational studies for this purpose. A Cox regression model can be ﬁtted to the IPD for each
of the 10 trials, to obtain partially adjusted hazard ratio estimates (that is unadjusted for age and BMI, but adjusted
for treatment). In the ﬁrst ﬁve trials, an extended Cox model can also be ﬁtted to the IPD to obtain fully adjusted
hazard ratio estimates (adjusted for age, BMI and treatment). Therefore, the ﬁrst ﬁve trials provide both θ^ iP and θ^ iF,
whilst the last ﬁve trials only provide θ^ iP . In the ﬁve trials with both, bootstrapping provides the within-study
correlations for the partially and fully adjusted log hazard ratio estimates; these ranged from 0.89 to 0.99. Applying
bivariate model (11) to all 10 trials using REML estimation gives a summary fully adjusted hazard ratio for smoking
of 1.92 (95% CI: 1.44 to 2.57; τ^F =0.18); however, a univariate meta-analysis of just the ﬁve trials providing fully
adjusted results gives a far higher summary hazard ratio of 2.70 (95% CI: 1.87 to 3.90; τ^P ≤ 0.001). The utilisation
of correlation thus reveals a lower adjusted hazard ratio than suggested by the ﬁve trials alone and a narrower
95% CI.
6.3. Longitudinal data
Jones et al. (2009) describe how to undertake a multivariate meta-analysis of randomised trials with longitudinal
continuous outcomes. These essentially extend the models introduced in section 4, where the multiple outcomes
now become multiple time points. The approach depends on whether one decides to model time as a factor or
as continuous. When time is to be treated as a factor, the ﬁrst step of the multivariate approach obtains the
treatment effect estimates at each time point, with their variances and within-study correlations. When time is
continuous with a linear trend assumed, differences in intercepts and slopes of the regression lines for the treatment
and control groups are estimated, again with their variances and within-study correlation. The second step is then a
multivariate meta-analysis of the trial estimates. Jones et al. (2009) show that accounting for the within-study
correlations is important, as the estimate and standard error of the meta-analysis result at each time point can
dramatically differ when naively assuming correlations are zero. However, they note that IPD studies are unlikely
to provide repeated measurements at all the same follow-up times, and therefore, if time is analysed as a factor,
similar time points (e.g. 6 months in trial 1 and 7 months in trial 2) may need to be grouped in order to proceed.
Trikalinos and Olkin consider multivariate meta-analysis of treatment effect estimates at multiple time points for
binary outcomes (Trikalinos and Olkin, 2012), and their formulae for deriving within-study correlations are easily
applied with IPD.
6.4. Development of multiparameter models for prognostic, dose–response and diagnostic research
Another area where the whole regression equation (including the intercept or baseline hazard, if modelled) is
important is for prognostic models (risk prediction models) (Steyerberg et al., 2013), where the ﬁtted equation
(e.g. logistic regression model) is needed to predict outcome risk for individuals based on their covariate values.
Given IPD from multiple studies, the same prognostic model could be ﬁtted in each study and their regression
coefﬁcients combined in a multivariate meta-analysis, to produce an overall model. This also allows the
heterogeneity of effects for particular prognostic factors to be quantiﬁed and may guide decisions about which
factors to include or exclude. For example, a factor with opposing effects across studies (e.g. OR> 1 in some
studies, OR< 1 in others) may be best excluded, as a model will be more reliable for practice if the direction of
a factor’s effect is consistent. If a factor has a consistent direction of effect but with varying magnitude (e.g. OR
of 2 in some studies but 3 in other studies), then its inclusion may be warranted to improve a model’s
discrimination, although potentially at the expense of reduced calibration (Debray et al., 2013).
Other uses of multivariate meta-analysis for multiparameter models are considered in detail elsewhere
(Gasparrini and Armstrong, 2011; Gasparrini et al., 2012). One particularly important application is for examining
dose–response relationships (Sauerbrei and Royston, 2011), for example, between the amount of alcohol intake
and risk of cancer (Greenland and Longnecker, 1992; Orsini et al., 2012). Interest is in how increasing the dose
or value of a factor increases (or decreases) the risk of a poor outcome. Linear and non-linear relationships can
be ﬁtted in each study, and then, a multivariate meta-analysis used to synthesise intercepts and slopes (for
linearity) and additionally other terms (such as spline terms, quadratic terms, etc.) that allow for non-linearity,
whilst accounting for the within-study correlation between all parameters. This produces a summary relationship
across studies, and misleading inferences are possible if correlation is ignored. For example, Orsini et al. (Orsini
et al., 2012) identify a linear trend between alcohol intake and lung cancer risk when using the multivariate
approach (p=0.03) but not when wrongly ignoring correlation (p= 0.58).
In diagnostic or screening test research, multivariate meta-analysis methods are being used to deal with
correlation between sensitivity and speciﬁcity. Typically, such methods have allowed one pair of sensitivity and© 2014 The Authors. Research Synthesis Methods published by John Wiley & Sons, Ltd. Res. Syn. Meth. 2015, 6 157–174
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0speciﬁcity estimates per study (Harbord et al., 2007). However, multiparameter models with multivariate meta-
analysis can accommodate multiple pairs of results per study, which arise when test accuracy estimates are
reported at multiple thresholds (Hamza et al., 2009; Riley et al., 2014). Monotonic relationships can be enforced
within and between studies, such that sensitivity decreases and speciﬁcity increases as the threshold increases,
and this enables a summary receiver operating characteristic curve to be produced.
6.5. Network meta-analysis
We have focused on multiple outcomes, but multivariate meta-analysis is also a natural framework for network
meta-analysis of multiple treatments (White et al., 2012). Network meta-analysis relies heavily on comparability
of different treatment comparisons (Salanti, 2012). IPD allows the analysis to be performed in an identical way
in all studies – using the same outcome deﬁnition, the same analysis model and the same methods for covariate
adjustment – and so should reduce the potential for inconsistency. Another possible source of inconsistency is
treatment-by-covariate interaction, and IPD – even if only in a subset of trials – allows models to be ﬁtted that
allow for this interaction (Saramago et al., 2012; Donegan et al., 2013).
Recent work has included multiple outcomes within the network meta-analysis (Ades et al., 2010; Schmid et al.,
2014; Efthimiou et al., 2014a; Efthimiou et al., 2014b) and includes an example where the ranking of treatments
changes when the correlation between the multiple outcomes are accounted for (Efthimiou et al., 2014b).
Within-study correlations are required when multiple outcomes are analysed or when multiarm trials are included
(White et al., 2012); they can be estimated by the methods described in the preceding texts.7. Discussion
We have described methods and applications of multivariate meta-analysis when IPD are available to calculate the
within-study correlations, which are otherwise often difﬁcult to calculate (Wei and Higgins, 2013b). Non-
parametric bootstrapping is the most generally applicable method to estimate within-study correlations, although
section 4 also described how to estimate them directly from a model for multiple continuous outcomes. By using
correlations, the multivariate approach offers many potential beneﬁts over separate univariate analyses. In our
examples, we showed how multivariate meta-analysis allows joint probability inferences across outcomes,
borrowing of strength (especially when some outcomes are (selectively) missing), more appropriate standard
errors (e.g. for longitudinal data), and novel options to estimate adjusted results and treatment–covariate
interactions. Many other novel applications are possible. For example, meta-analysis of surrogate outcome studies
(Buyse et al., 2000; Michiels et al., 2009; Daniels and Hughes, 1997; Gail et al., 2000; Buyse, 2009), where a primary
aim is to estimate and use the correlation between a surrogate outcome and a true outcome (such as between
CD4 count and AIDS); prognostic studies where the absolute survival risk at multiple time points is needed (Arends
et al., 2008); and investigations of the association between treatment effect and baseline risk (Van Houwelingen
et al., 2002; Senn, 2010; Van Houwelingen et al., 1993).
We assumed that IPD are available in all studies. However, many of the methods and applications discussed in
this paper allow the incorporation of additional non-IPD studies, if they directly provide estimates of (or data
informing) some of the effects for the outcomes of interest. For example, adjusted prognostic factor results are
notoriously prone to selective reporting bias, with non-signiﬁcant adjusted results commonly excluded and only
unadjusted or partially adjusted results shown. The bivariate model (11) allows non-IPD studies that provide only
partially adjusted (or unadjusted) results to be included, and these may then still contribute (through the
between-study correlation and any within-study correlations in IPD studies) towards the pooled adjusted result.
One might expect the pooled adjusted estimate to be lower after accounting for studies that do not report
adjusted results, as a result of their selective reporting. Even when non-IPD studies provide all the effects of
interest, they are unlikely to provide their within-study correlations. Bujkiewicz et al., 2013 suggest including these
studies by placing an informative prior distribution for their missing within-study correlations, based on the
within-study correlation in available IPD studies. Speciﬁcally, they apply a double bootstrap procedure in an IPD
study to estimate the within-study correlation and its uncertainty, which are then used to specify a prior
distribution for the missing within-study correlations in other studies.
Some of the approaches discussed could also be ﬁtted using a one-stage IPD model, in particular the
continuous outcome models in section 4 (Riley et al., 2008b), the longitudinal modelling in section 6.4 (Jones
et al., 2009), and the multiparameter modelling in section 6.5 (Orsini et al., 2012). This may be quicker and
advantageous with rare events or small patient numbers, for example, to allow for more exact binomial or
multinomial sampling distributions to be modelled within studies (Trikalinos et al., 2013; Trikalinos et al., 2014;
Stijnen et al., 2010; Hamza et al., 2009). One-stage analysis may also be beneﬁcial for advanced modelling of
competing risks and correlated survival outcomes (Rondeau et al., 2011) and also multistate models (Price et al.,
2011; Ades et al., 2010), which we have not considered here. However, one-stage models can be more
computationally intensive, are difﬁcult to specify for survival or mixed outcomes, and can have convergence
issues (Riley et al., 2007b), which – in our experience – is particularly problematic when some outcomes are© 2014 The Authors. Research Synthesis Methods published by John Wiley & Sons, Ltd. Res. Syn. Meth. 2015, 6 157–174
R. D. RILEY ET AL.missing across studies. Both one-stage and two-stage models allow non-IPD studies to be combined with IPD
studies where relevant (Riley et al., 2008b; Riley and Steyerberg, 2010; Sutton et al., 2008; Donegan et al., 2013;
Riley et al., 2007c).
Finally, we recognise that the multivariate model is not without limitations (Jackson et al., 2011), even when IPD
are available. In particular, there can be difﬁculty estimating between-study correlations (Riley et al., 2007b), and
the use of a trial-level multivariate normal distribution assumes a linear relationship in the true effects across trials,
which is hard to validate. In both one-stage and two-stage frameworks, the multivariate normal distribution is
commonly assumed for the true effects across studies because it is convenient, can be implemented in most
statistical software packages through REML estimation, and naturally extends the univariate setting where a
normal distribution is often used. However, Baker and Jackson, 2008 note that, unlike within studies where the
central limit theorem suggests that normal sampling distributions of effect estimates will occur when sample sizes
become large, between studies “the Central Limit Theorem does not really imply anything for the distribution of
the random effect ....We can only appeal to the Central Limit Theorem here with the vague idea that the unknown
source of variation between studies might be the sum of several factors”. If one wishes to avoid the multivariate
normality assumption between studies, then non-parametric estimation methods can be used such as MM
(Jackson et al., 2010; Jackson et al., 2013; Chen et al., 2012; DerSimonian and Laird, 1986). However, if interested
in the joint predictive distribution of effects, then a parametric speciﬁcation is preferable. Lee and Thompson,
2008 suggest a number of ﬂexible alternatives to the normality assumption, for both univariate and bivariate
settings, whilst a longer tailed distribution has been proposed in the univariate setting (Baker and Jackson,
2008). Recently, in the setting of test accuracy studies where sensitivity and speciﬁcity are of interest, a one-stage
meta-analysis using a beta-binomial model has been proposed (Kuss et al., 2014), with the correlation between
sensitivity and speciﬁcity accounted for using bivariate copulas.
In conclusion, with its potential statistical beneﬁts and a wide range of areas for application, multivariate meta-
analysis is likely to gain increasing interest in the future, and we have shown how to implement the approach
when IPD are available from multiple studies.Acknowledgements
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